Related Experiment Videos
J-shaped mortality relationship for uric acid in CKD
Mohamed E Suliman1, Richard J Johnson, Elvia García-López
1Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Insights
High and low serum uric acid levels increase mortality risk in chronic kidney disease (CKD) patients. The lowest mortality risk was observed in patients with moderate uric acid levels, indicating a J-shaped association.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Clinical Chemistry
Background:
- Hyperuricemia is prevalent in chronic kidney disease (CKD) patients.
- The association between hyperuricemia and cardiovascular mortality in CKD is not well-established.
Purpose of the Study:
- To investigate the relationship between serum uric acid levels and all-cause mortality in patients with advanced CKD.
- To explore the association of uric acid with comorbidities in this population.
Main Methods:
- A cohort of 294 incident CKD stage 5 patients starting renal replacement therapy was studied.
- Patients were stratified into three groups based on serum uric acid levels: low, middle, and high quintiles.
- Survival analysis was performed over a mean follow-up of 27 months, with adjustments for multiple clinical factors.
Main Results:
- A J-shaped association was observed between serum uric acid levels and all-cause mortality.
- Both high and low serum uric acid levels were associated with increased mortality risk compared to moderate levels.
- Uric acid levels correlated with markers of dyslipidemia, inflammation, and calcium/phosphate metabolism.
Conclusions:
- Serum uric acid levels exhibit a J-shaped relationship with all-cause mortality in CKD stage 5 patients.
- Moderate serum uric acid levels are associated with the lowest mortality risk.
- Uric acid is linked to key CKD comorbidities including metabolic disturbances and inflammation.
Background:
Hyperuricemia is a common feature in patients with chronic kidney disease (CKD). Hyperuricemia has been associated with increased cardiovascular mortality in the general population, but less is known about this association in patients with CKD.
Methods:
To explore possible associations of serum uric acid with all-cause mortality and comorbidity in patients with CKD, we studied 294 incident patients with CKD stage 5 (185 men; age, 53 +/- 12 years) starting renal replacement therapy with a median glomerular filtration rate of 6.4 mL/min/1.73 m(2) (0.11 mL/s/1.73 m(2); range, 0.8 to 14.3 mL/min/1.73 m(2) [0.01 to 0.24 mL/s/1.73 m(2)]). Survival was determined from the day of examination and during a mean follow-up period of 27 months (range, 3 to 72 months); 94 patients died. Patients were divided into 3 groups based on serum uric acid levels (low quintile, 3 middle quintiles, and high quintile).
Results:
In a nonadjusted analysis, patients in the high quintile, followed by patients in the low quintile, had greater all-cause mortality compared with patients in the 3 middle quintiles (log-rank test chi-square, 6.8; P = 0.03). After adjusting for age, sex, glomerular filtration rate, cholesterol level, phosphate level, C-reactive protein level, cardiovascular disease, diabetes mellitus, diuretics, and allopurinol treatment, the association showed a "J-shaped" association with hazard ratios of 1.96 (confidence interval, 1.10 to 3.48; P = 0.02) for the high quintile and 1.42 (confidence interval, 0.76 to 2.66; P = not significant) for the low quintile. Moreover, uric acid levels correlated positively with levels of triglycerides, phosphate, C-reactive protein, and intracellular adhesion molecule 1 and negatively with levels of calcium, high-density lipoprotein cholesterol, and apolipoprotein A.
Conclusion:
Serum uric acid levels showed a J-shaped association with all-cause mortality, with the lowest risk in the 3 middle quintiles. Moreover, uric acid level was associated with calcium/phosphate metabolism, dyslipidemia, and inflammation.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Chronic Kidney Disease I: Introduction
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
The pKa of a drug,...
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction